STRATEGIC NEWS WATCH — June 29, 2026
|
Viridian’s FDA approval of Lumvoa ends Amgen Tepezza’s near-monopoly on the $2 billion thyroid eye disease market, the sharpest of a deal-and-data-heavy session that also saw two acquisitions and a closely watched immunology flop. Today’s top developments:
|
What to Watch
- Lumvoa launch vs. Tepezza — Watch how fast Viridian stands up commercial infrastructure and whether its broader active-plus-chronic label translates into real share against Amgen’s deeply entrenched Tepezza franchise.
- Ipsen-Kartos close and navtemadlin readout — Track the expected Q3 2026 close and Phase 3 POIESIS progress in myelofibrosis; clean data would validate the up-to-$1.75B bet and support a potential 2028 launch.
- Zymeworks-Theravance integration — Watch deal-close timing, Viatris’s role in Yupelri commercialization, and how Zymeworks balances near-term respiratory cash flow against its bispecific oncology pipeline.
- Biotech R&D retrenchment — BioCryst’s full exit from internal discovery and Biogen’s Apellis pruning point to a widening pattern of cost rationalization; watch which mid-caps next trade proprietary discovery for partnered or late-stage assets.
- Crowded immunology pipelines — With Evommune’s CSU miss and startup Talawar’s bispecific eczema bet both in play, watch whether differentiated mechanisms can dislodge entrenched leaders like Novartis in hives and Dupixent in atopic dermatitis.
This brief highlights the edition’s top stories. Read the full June 29, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.